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Background: Emu oil is a product of animal origin used for the treatment of inflammation, burns etc. as a part of
aboriginal medicine in Australia. Crohn’s disease is a common inflammatory manifestation in humans and other
animal species relating to the ulceration and digestive disturbances in upper gastro-intestinal tract. Aloe vera is
commonly used substance from plant sources for inflammation, wound healing and various other properties. Given
the difference in the source of the substances all the while playing a similar therapeutic role in different parts of the
world, the present investigation was undertaken to evaluate the protective effect of aloe vera and emu oil alone
and in combination; in comparison to sulfasalazine (Allopathic drug) as an alternative for the treatment of Crohn’s
disease.
Methods: Wistar albino rats were divided into six groups with two sub-groups of six animals each. After
pre-treating the animals with sulfasalazine, aloe vera, emu oil and their combination for five consecutive days, the
animals were sub-cutaneously administered indomethacin on 4th and 5th day and each sub-group was sacrificed on
day 6 and 9. After sacrifice, serum and intestine of these animals was collected. Intestine length from duodenum till
caecum was measured for estimating relative organ weight and disease activity index. Part of intestine was
preserved in formalin for histopathology while the rest was used for analysis of oxidative parameters and
myeloperoxidase. Serum collected was used for measuring alkaline phosphatase and cholesterol.
Results: Assessment of the parameters in treatment groups indicated that the combination of aloe vera and emu
oil resulted in better protection by suppressing the oxidative (P < 0.05) and histomorphological changes indicating
a enhanced effect of these two agents which was found to be better than sulfasalazine.
Conclusion: The combination of emu oil and aloe vera exhibited enhanced effect resulting in significant protection
from indomethacin induced ulceration. This might be due to the different mechanism of anti-inflammatory effects
(Salicylic acid in aloe vera and n3, n6 fatty acids acting as pseudosubstrates to cyclooxygenase enzyme) of
components of the animal and plant products tested.
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Crohn’s disease (CD) is a chronic condition observed in
human and animal species affecting gastrointestinal tract.
It is one of the forms of Inflammatory Bowel Disease
(IBD) complex, while the other being Ulcerative Colitis
(UC) [1]. Incidence of this condition, which doesn’t have a
specific aetiology, has been on the increase owing to
multitude of factors such as increased westernisation of* Correspondence: vemubhaskar@rediffmail.com
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(http://creativecommons.org/publicdomain/zehabits (food and living), pollution, lowered immunity due
to poor nutrition etc. [1]. Presently, the drugs used in the
treatment of IBD are aimed at overall immunosuppression
(corticosteroids) or mediator specific suppression (anti-
TNF alpha, anti IL-6 antibodies etc.). Drugs used in the
therapy of IBD include anti-inflammatory agents such as
mesasalazine, sulfasalazine, corticosteroids, immunosup-
pressives (Azathioprine, 6-mercaptopurine), antibacterials
(metronidazole, ornidazole, clarithromycin), biologics
(infliximab, adalimumab, certolizumab pegol etc.) and
probiotics (Saccharomyces boulardii, Lactobacillus sp, Bifi-
dobacterium sp.) [2].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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been tested against IBD but with limited success. These
include amla, wormwood, eicosapentaenoic acid, doc-
osahexaenoic acid, fish oil, curcumin, linolenic acid
etc. [3–6]. Rahimi et al. [7] reported some plants of
Iranian origin having therapeutic effect against IBD,
which include Pistacia lentiscus, Commiphora mulkul,
Terminalia chebula, Lepidum sativum and Althaea
sp. After perusal of the literature, it was found that
aloe vera (Aloe barbadensis Miller) is one of the few
plant products which has been known to offer moder-
ate protection against IBD and has successfully en-
tered clinical trials [8].
Emu oil was originally used by the aboriginals in
Australia to treat pain and arthritic conditions. It is ex-
tracted from the retroperitoneal and sub-cutaneous fat
of the flightless bird Emu (Dromaius novaehollandiae)
[9]. Reports suggest that emu oil consists of high levels
of unsaturated fatty acids (upto 50 %) such as oleic acid,
linoleic acid, linolenic acid, palmitoleic acid etc. [10].
These fatty acids are also found in the liver oil of marine
animals and were proven to be highly efficacious in
treating inflammatory conditions [11]. Emu oil has been
tested in arthritis, auricular, intestinal inflammation,
hypercholesterolemia, burns etc. [9, 12–16].
Animal models for experimental replication of IBD
can be spontaneous (cotton top tamarind model in mon-
keys), induced (Acetic acid/Oxazolone/Dextran Sulfate
Sodium/TNBS) or through genetic manipulations (HLA-
B27 transgenic rat/IL-2 deletion/IL-10 deletion/αβ TCR
deletion/TGF-β1 deletion/Gi2α deletions in mice) [17].
Of these models due to the economic and ease of work-
ing and repeatability, chemically induced models are
favoured. In induced models, TNBS and DSS are the
commonly used models in mice whereas acetic acid and
indomethacin models are commonly used in rats. Due
to the ease of induction and the wide relevance of the
model to clinical recurrence, indomethacin was used in
the present study, which was reported to cause clinical
condition that is similar in picture as well as mechanism
to that of CD [18–20]. Several authors reported that the
histomorphological picture of indomethacin induced in-
flammation has a similar picture to that of crohn’s dis-
ease indicating similar mechanisms. Also, indomethacin
can induce as well as reactivate the clinical occurrence
of IBD. Taking the above factors into consideration, the
present study was planned to test the effect of aloe vera
alone and in combination with emu oil against indo-
methacin induced CD [21].
Methods
Indomethacin, emu oil and aloe vera gel extract were
obtained from Tablets India Ltd., VR3 Emu farms &
hatchery unit and Natural Remedies®, respectively.Sulfasalazine was procured from Sigma-Aldrich®, USA.
All the chemicals used in the study were of analytical
grade.Animals
Female wistar albino rats weighing 120-180 g were sup-
plied by the Department of Laboratory animal medicine
unit, Chennai. The animals were provided with ad libi-
tum feed (M/S Tetragon Chemie Pvt. Ltd., Bangalore,
India) and water. The experiments were carried out as
per CPCSEA guidelines after obtaining the requisite ap-
proval from the Institutional Animal Ethics Committee
(Lr.No1831/DFBS/E/IAEC/2010 dt.24.06.2011). Rats
were divided into six groups with two sub groups of 6
animals each. First and second group served as healthy
and negative control. The third group was administered
sulfasalazine (100 mg/Kg body weight per os), fourth
group – Aloe vera leaf gel extract (@ 400 mg/Kg body
weight per os), fifth group – emu oil (@10 ml/Kg body
weight per os) and sixth group – combination of aloe
vera and emu oil (similar to the dose used in groups 4 &
5) for five consecutive days. Groups two through six
were given sub-cutaneous indomethacin (5 %) prepared
in 5 % sodium carbonate and administered at a dose rate
of 10 mg.kg-1 on day 4 and 5 of study. On days six and
nine, each sub group of animals across all groups were
sacrificed. Intestine of these animals was collected from
duodenum to caecum and washed with ice cold normal
saline.Oxidative and inflammatory tests
The length and weight of the intestine along with body
weight of the animal was measured for the estimation of
DAI (Disease Activity Index) and ROW (Relative Organ
Weight).
DAI =Weight of the intestine (g)/length of the intes-
tine (cm)
ROW=Weight of the intestine (g)/body weight of the
animal (g)
Macroscopic scoring was analysed by the method of
Shirke [22]. Intestinal tissue was collected and stored at
-20 °C till further analysis. The portion of intestine be-
fore the ileo-caecal junction was collected for
homogenization (Heidolph Silent Crusher®, Germany) in
phosphate buffer (pH 7.2, 50 mM). Homogenate
(10 % W/V) was divided into three parts – one part
mixed with 10 % trichloroacetic acid for measurement of
reduced glutathione, other part for the measurement of
lipid peroxidation and the third part was centrifuged at
15,000 g for 60 min at 4 °C and the supernatant was
used for measurement of superoxide dismutase, catalase
and glutathione peroxidase.
Table 1 Composition of emu oil (GC-MS analysis)
Fatty acid Percent (%)
Myristic acid (Saturated) 0.71
Palmitic acid (Saturated) 23.87
Stearic acid (Saturated) 10.76
Oleic acid (n9) 41.84
Linoleic acid (n6) 12.43
Linolenic acid (n3) 0.29
Palmitoleic acid (n7) 4.73
Total saturated fatty acid 35.34
Total unsaturated fatty acid 59.29
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Thiobarbituric acid reactive substances were measured
as per the procedure of Yagi [23]. Homogenate obtained
was deproteinised using 10 % TCA followed by addition
of 2 ml of thiobarbituric acid (46 mM thiobarbituric acid
(TBA) in 1 N NaOH) and boiled for 30 min. Samples
were centrifuged if found turbid. Absorbance was mea-
sured at an OD of 532 nm. TBARS was expressed as nM
of MDA (Malonaldehyde) per gram of tissue.
Assay of catalase
Catalase was measured as per the protocol of Caliborne
[24]. Supernatant (0.2 ml) was added to 1 ml of hydrogen
peroxide (30 mM hydrogen peroxide in 0.1 M phosphate
buffer pH 7). Absorbance was measured for 3 min at a
wavelength of 240 nm and the change in absorbance per
minute was used to calculate activity using molar extinc-
tion co-efficient and activity is expressed as mM of hydro-
gen peroxide decomposed per minute per mg of protein.
Assay of superoxide dismutase
Superoxide dismutase was measured according to Mark-
lund and Marklund [25]. Assay mixture consisted of
2 ml of Tris-HCl (0.1 M, pH 8.2), 1.5 ml of distilled
water and 0.5 ml of supernatant. Reaction was initiated
by addition of 0.5 ml of pyrogallol (2 mM pyrogallol in
50 mM of Tris-HCl pH 7.4). A control has same assay
mixture with addition of 2 ml distilled water instead of
1.5 ml in samples. Change in absorbance was recorded
over 3 min period at a wavelength of 420 nm and change
in absorbance per minute followed by enzyme activity
which corresponds to amount of enzyme that inhibits
auto-oxidation of pyrogallol by 50 % was calculated and
expressed per mg of protein.
Assay of glutathione peroxidase
It was assayed as per the method of Rotruck et al. [26].
Reaction mixture consists of 0.4 ml phosphate buffer
(pH 7), 0.1 ml sodium azide (10 mM), 0.2 ml reduced
glutathione (4 mM) and 0.2 ml of supernatant followed
by 0.1 ml of 30 mM hydrogen peroxide finally making
the total volume to 2 ml with distilled water. After
10 min incubation at room temperature, add 3 ml of dis-
odium phosphate (0.3 M) and 1 ml of Dithiobis-2-
nitrobenzoic acid (DTNB). Mix well and measure ab-
sorbance at a wavelength of 412 nm. Enzyme activity is
expressed as micromoles of reduced glutathione utilised
per min per milligram of protein.
Assay of reduced glutathione
Reduced glutathione was measured as per Moron et al.
[27]. It is based on the reaction of reduced glutathione
with DTNB to give a compound that absorbs light at a
wavelength of 412 nm. Method involves addition of0.1 ml of homogenate with 0.9 ml of phosphate buffer
(0.2 M, pH 8) followed by 2 ml (0.6 M DTNB) and
measurement of the absorbance. It is expressed as μg of
reduced glutathione per gram of tissue.
Assay of myeloperoxidase
Estimation of myeloperoxidase was done as per the pro-
cedure of Krawisz et al. [28]. Half gram of sample was
homogenised with 10 volumes of ice cold 50 mM Potas-
sium phosphate buffer (pH 6) containing 0.5 % Hexade-
cyl Trimethyl Ammonium Bromide (HETAB). The
resultant homogenate was subjected to sonication for
15 s, followed by centrifugation at 40C, 12,000 g for
20 min. To the 0.1 ml supernatant, 2.9 ml of 50 mM
phosphate buffer in 0.0005 % hydrogen peroxide (H2O2)
was added. The change in absorbance over four minutes
at a wavelength of 460 nm was observed from which the
change in absorbance per minute was calculated. One
unit of myeloperoxidase activity was defined as the
change in absorbance per minute at room temperature.
Serum was separated for analysis of alkaline phosphat-
ase (ALP) and cholesterol using Robonik® and Agappe®
Diagnostics Ltd. kits as per manufacturer instructions.
Intestine was stapled to cardboard to prevent shrinkage
during tissue fixation in 10 % formalin. Sections were
stained using Haematoxylin and Eosin stain [29]. All the
values were expressed as Mean ± S.E. Values were statis-
tically analysed using one way ANOVA followed by
post-hoc analysis through tukey’s test using SPSS Ver-
sion 20. P < 0.05 was considered significant.
Results
Composition of Emu oil
Emu oil was analysed using GC-MS and the fatty acid
composition is presented in Table no. 1 [10].
Macroscopic scoring, DAI, ROW, ALP and cholesterol
The findings of the present investigation are tabulated in
Tables 1, 2 and 3. Gross examination revealed no ulcer-
ation in control group but severe ulceration was noticed
Table 2 Effect of the drug treatments on the relative organ weight, disease activity index, macroscopic scoring and serum
biochemical parameters in indomethacin induced CD in rats
Macroscopic scoring ROW DAI (g/cm)
Group day 6 day 9 day 6 day 9 day 6 day 9
Control - - 0.033a ± 0.008 0.033a ± 0.001 0.063a ± 0.0013 0.061a ± 0.0016
Indomethacin 2.20d ± 0.20 1.43b ± 0.20 0.054b ± 0.002 0.056d ± 0.001 0.092b ± 0.003 0.082b ± 0.0017
Sulfasalazine 2.00cd ± 0.32 0.71a ± 0.36 0.037a ± 0.003 0.041bc ± 0.001 0.0681a ± 0.0013 0.063a ± 0.0027
Aloe vera 1.60bcd ± 0.25 0.50a ± 0.22 0.048ab ± 0.0006 0.049c ± 0.0021 0.067ab ± 0.0047 0.064a ± 0.0016
Emu oil 1.00abc ± 0.32 Nil 0.045ab ± 0.004 0.039ab ± 0.003 0.067a ± 0.0033 0.064a ± 0.0032
Aloe vera and emu oil combination 0.60a ± 0.25 Nil 0.041ab ± 0.0024 0.042bc ± 0.001 0.077ab ± 0.0062 0.063a ± 0.0045
Day 6 Day 9
Group Cholesterol (mg/dL) ALP (U/L) Cholesterol (mg/dL) ALP (U/L)
Control 63.24a ± 2.14 103.23a ± 1.01 68.45a ± 6.58 106.77a ± 12.37
Indomethacin 61.74a ± 3.045 272.28c ± 25.18 49.80a ± 5.42 274.33c ± 11.74
Sulfasalazine 50.69a ± 9.23 182.67b ± 23.76 52.36a ± 1.53 224.40bc ± 17.81
Aloe vera 61.28a ± 9.27 182.66b ± 8.71 62.38a ± 4.22 169.05abc ± 41.01
Emu oil 57.75a ± 7.30 138.54ab ± 8.12 64.35a ± 4.65 153.50ab ± 21.45
Aloe vera and emu oil combination 56.44a ± 9.48 177.32b ± 20.09 54.98a ± 8.44 154.60ab ± 29.65
All the values were expressed as Mean ± S.E. (n = 6) and means bearing different superscripts in a column differ significantly
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by day 9 of the study (Fig. 1). Interestingly, there were
no ulcers in emu oil and combination groups on day
nine. Upon macroscopic scoring it was evident that emu
oil and combination groups had significant affect when
compared to sulfasalazine group (Fig. 1 and Table 2).
Similar pattern was observed in serum alkaline phos-
phatase levels along with DAI and ROW parameters,
wherein there was significant elevation in indomethacin
group throughout the study period but the treatment
with emu oil and combination had significantly lowered
it to near normal levels (Table 2). Since emu oil was be-
ing administered, serum cholesterol was analysed and no
significant alterations developed during the study period.Table 3 Effect of drug treatments on the intestinal tissue pro-oxidan






inhibit 50 % pyrogallol
autoxidation/min/mg
protein)
Control 8.73b ± 0.01 6.15b ± 0.55
Indomethacin 2.37a ± 0.07 1.73a ± 0.28
Sulfasalazine 6.12ab ± 1.37 3.31a ± 0.33
Aloe vera 4.26ab ± 0.5 2.74a ± 0.33
Emu oil 5.97ab ± 0.50 2.95a ± 0.44
Aloe vera and emu oil
combination
6.07ab ± 1.02 3.22a ± 0.26
All the values were expressed as Mean ± S.E. (n = 6) and means bearing different suOxidative status, myeloperoxidase and histopathology
Assessment of the oxidative parameters indicated an im-
provement in the overall antioxidant state of intestine in
emu oil and combination groups as compared to aloe vera
and sulfasalazine groups, which in turn were better than
the indomethacin group (Tables 3 and 4). Intestines of
control group were normal with presence of goblet cells
and villi architecture (Fig. 2). Noticeable changes in the
neutrophil infiltration, transudate accumulation in lamina
propria, denudation of epithelium etc. have been observed
in indomethacin group. These changes have been pre-
vented to some extent by treating with sulfasalazine and
aloe vera as observed in histopathological sections but
neutrophil infiltration was still severe as indicated byt and antioxidant parameters on day six of sacrifice in










5.17c ± 0.49 2.85a ± 0.25 54.58d ± 1.16 15.40a ± 0.84
1.44a ± 0.35 27.01d ± 1.47 27.77a ± 1.18 63.29c ± 4.79
3.52bc ± 0.22 11.90c ± 0.59 31.83ab ± 2.29 39.06b ± 1.03
2.91ab ± 0.19 10.96c ± 0.58 34.75ab ± 1.25 39.89b ± 2.25
3.67bc ± 0.42 8.36bc ± 0.91 41.71bc ± 2.13 35.36b ± 0.64
3.97bc ± 0.68 5.92ab ± 1.40 46.58cd ± 3.06 33.66b ± 4.14




Fig. 1 Macroscopic lesions of rat intestine (Caecum and Ileum). a Healthy control. b Necrosis of tissue in caecum of indomethacin treated rats (c)
Longitudinal and pin point ulceration in ileum of indomethacin treated rats (d) Necrosis and granulation of caecum in sulfasalazine treated rats
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ing indicative of inflammatory exudate. On the other
hand, in the groups treated with emu oil and combination,
the degenerative changes were least along with trace pres-
ence of goblet cells and villi indicating superior protection
from the damage caused by indomethacin. Emu oil and its
combination with aloe vera appeared to have better effect
among all the treatment groups.
Discussion
Rats were treated with indomethacin to induce CD like
condition and the efficacy of aloe vera and emu oil in
comparison to sulfasalazine was evaluated. Indomethacin
administration resulted in ulceration of intestine incaecum and ileum. The process of ulceration can be di-
vided into topical and resolution phases. In the former,
sloughing of mucus and epithelial layers along with re-
duction in the protection offered by phosphatidyl cho-
line is observed [30–33]. NSAIDs (Non steroidal anti-
inflammatory drugs) could remove or replace phosphati-
dyl choline leading to production of simple toxic or
super toxic micelles. Due to entrapment and accumula-
tion of indomethacin in epithelial cells, uncoupling of
oxidative phosphorylation, reduction of ATP levels, al-
tered Ca++ homeostasis, ROS (Reactive Oxygen Species)
production and cell death results [34]. It has been re-
ported to alter blood circulation leading to venous stasis,
stunting of villi and accumulation of neutrophils,
Table 4 Effect of the drug treatments on the intestinal tissue pro-oxidant and antioxidant parameters on day nine of sacrifice in
indomethacin induced CD in rats

















Control 8.53c ± 0.29 6.46b ± 0.55 5.70c ± 0.4 2.39a ± 0.29 56.68c ± 2.48 16.63a ± 1.85
Indomethacin 3.11a ± 0.31 1.67a ± 0.166 1.56a ± 0.08 30.62c ± 4.28 24.62a ± 1.72 46.65c ± 2.27
Sulfasalazine 6.11abc ± 0.94 3.47ab ± 0.19 3.25ab ± 0.52 13.68b ± 1.92 31.49ab ± 3.02 25.46ab ± 1.77
Aloe vera 4.35ab ± 0.52 3.20a ± 0.18 2.47a ± 0.19 15.82b ± 0.99 36.76ab ± 1.59 32.65b ± 2.64
Emu oil 6.26abc ± 0.74 3.75ab ± 0.16 4.48bc ± 0.69 8.93ab ± 0.63 44.75bc ± 2.45 30.85b ± 3.80
Aloe vera and emu oil
combination
6.91bc ± 0.18 4.55ab ± 0.15 4.95bc ± 0.12 8.33ab ± 0.80 37.66bc ± 5.23 29.68b ± 2.07
All the values were expressed as Mean ± S.E. (n = 6) and means bearing different superscripts in a column differ significantly
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dotoxins released by enteric bacteria, further intensifying
the inflammation [35].
In the resolution phase, due to inhibition of COX-1 en-
zymes there is reduction in the synthesis of anti-
inflammatory mediators. It has been reported that COX-1
expression is highest in small intestine of humans and any
non-selective NSAID mediated injury was was restricted
to upper gastrointestinal tract in humans indicating the
role of COX-1 in resolution phase, required for synthesis
of anti-inflammatory prostaglandins. The NSAID medi-
ated injury in rats was limited to lower GI tract, due to
differences in the distribution of COX-1 enzyme [36].
DAI and ROW parameters are based on body weight,
intestine weight and length. CD might hamper nutrient
absorption ensuing in weight reduction. Since, the
present study is for a short duration, ratio of organ to
body weight has been considered assuming that the body
weight has been normalised between different groups.
Any reduction in body weight and increase in weight of
intestine (accumulation of fluids due to inflammation)
would increase ROW. Similarly, inflammation would re-
sult in shortening of intestine and increase in DAI. ALP
is a non specific marker of intestine and any increase in
control conditions are indicative of intestinal affection.
Cholesterol, a major indicator of lipid absorption did not
show any significant changes even after administration
of emu oil, which might be due to the reduction in the
bile flow [37].
Myeloperoxidase is an enzyme present in the neutro-
phils, which helps in the production of hypochlorous
acid (HOCl) that has antibacterial properties and depoly-
merises gastrointestinal mucin, peroxidise lipid and pro-
tein [38] through the release of hydroxyl and chloride
radicals resulting in oxidative stress [39]. It also has
chemotactic activity, thereby increasing the inflamma-
tory cell population and intensifying oxidative stress.
Aloe vera and emu oil, through their antioxidant activitymight have resulted in combating these free radicals
thereby offering protection to intestine. Any amount of
oxidative stress would be perilous to intestine as it is
one of those organs which have poor defensive mecha-
nisms against oxidative stress [40].
It is established that sulfasalazine acts on NF-kB (Nu-
clear Factor Kappa B) gene and has anti-inflammatory
and antioxidant activity [41]. Similarly, fractions of emu
oil might act at gene level and down regulate NF-kB
resulting in anti-inflammatory activity as reported by
Borniquel and co-workers for nitrated oleic acid in IBD
[42]. Once inflammatory cell migration and tissue injury
are inhibited overall antioxidant status of intestine gets
improved. Even though there was reduction in the num-
ber of ulcers in emu oil and combination groups on day
nine, there were multiple microscopic ulcerations in sec-
tions of all groups except group I.
The mechanism of anti-inflammatory activity of emu
oil and aloe vera might be through intervening at mul-
tiple steps in the process of initiation and intensification
of intestinal inflammation. Aloe vera has various compo-
nents that act as antioxidant and anti-inflammatory
agents. These include alprogen that inhibits mast cell
degranulation thereby inhibiting the release of histamine
and leukotrienes [43], along with salicylic acid and β-
sitosterol which have anti-inflammatory activity [44].
Similarly, PUFA’s in emu oil could act as false substrates
to inflammatory enzymes resulting in synthesis of pros-
taglandins, leukotrienes and resolvins. Prostaglandins (3
series) and leukotrienes (5 series) have poor pro-
inflammatory activity whereas resolvins have been re-
ported to possess anti-inflammatory activity through
ChemR23 (G protein coupled receptor involved in in-
flammation) [45]. Anti-inflammatory effect of emu oil
could also be attributed to its role in inhibiting indo-
methacin accumulation, translocation of intestinal biota
to lamina propria, providing antioxidant activity etc.
Emu oil composition too indicates that higher levels of
Fig. 2 Microscopic picture in sections obtained from ileo-caecal region in rats sacrificed on day nine. a Healthy control (b) Ulceration, loss of villi,
infiltration of neutrophils and eosinophilic staining of lamina propria in indomethacin treated rats (c) Loss of villi architecture and infiltration of
neutrophils in sulfasalazine treated rats (d) Loss of caecal glands, ulceration and eosinophilic staining of lamina propria in aloe vera treated rats (e)
Presence of caecal glands and partial loss of epithelium observed in emu oil treated rats (f) Normal caecal architecture with villi projections and
normal staining of lamina propria in rats treated with the combination of aloe vera and emu oil
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thesis of the pro-inflammatory mediators with weak pro-
inflammatory and potent anti-inflammatory activities.
So, aloe vera and emu oil when administered simultan-
eously would act at different steps of inflammation
resulting in wholesome effect.
Conclusion
In the present scenario, finding a specific molecule for
the treatment of idiopathic conditions is difficult. Awholesome agent that can act at various levels of the in-
flammatory process is required. This is possible to some
extent vide the use of complex agents such as plant
extracts or oils (animal and/or vegetable origin) in en-
capsulated form for drug delivery. The present investiga-
tion has revealed an interesting fact, that through
simultaneous use of emu oil and aloe vera gel extract, a
enhanced effect in the therapy of indomethacin induced
CD model is produced, which is perceptible through
biochemical and oxidative parameters. This study
Vemu et al. BMC Complementary and Alternative Medicine  (2016) 16:55 Page 8 of 9therefore corroborates the use of emu oil and aloe vera
for intestinal inflammation as an alternative medicine
and suggests the use of encapsulated preparations for
better therapeutic effect.
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